VAXCYTE INC. - COMMON

Vaxcyte Appoints Whitney Jones as Chief People Officer

16 Jan 2024 15:01:00 By Nasdaq GlobeNewswire

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

04 Jan 2024 15:01:42 By Nasdaq GlobeNewswire

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

04 Dec 2023 17:35:00 By Nasdaq GlobeNewswire

Vaxcyte Appoints Jacks Lee to Board of Directors

28 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

27 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 15:03:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

31 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

19 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 15:03:00 By Nasdaq GlobeNewswire

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

11 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the Jefferies Healthcare Conference

01 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

08 May 2023 15:03:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

03 May 2023 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 Apr 2023 16:25:10 By Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $500 Million Public Offering

18 Apr 2023 23:26:49 By Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

17 Apr 2023 15:05:14 By Nasdaq GlobeNewswire

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

17 Apr 2023 05:30:00 By Nasdaq GlobeNewswire